The
global market consist of players such as AbbVie, Allergan plc, Chiesi
Farmaceutici S.p.A., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Novartis
AG, Pharmaxis Ltd, PTC Therapeutics, and Vertex Pharmaceuticals Incorporated
are some of the prominent players at the forefront of competition in the global
cystic fibrosis market and are profiled in MRFR Analysis report.
Global Cystic Fibrosis Market - Overview:
According
to a recent study report published by the Market Research Future analysts, the
global cystic fibrosis (CF) therapeutics market is growing at a double digit CAGR. The major growth in the cystic
fibrosis market was observed with the introduction of Kalydeco drug by Vertex
pharmaceutical in 2012. There has been constant development of new drugs and
therapies for treating cystic fibrosis. Cystic fibrosis foundation (CFF) has
always been in support of the companies involved in the research and
development of the cystic fibrosis drugs. The financial support from CFF is influential
in the growth of the cystic fibrosis market worldwide.
That being said, there are few hurdles as well in growth of this
market. Currently there are approximately 1900 identified CFTR mutations that
are responsible for the development of the disease condition. Many are yet to
be identified. At present, treatments are available for nearly half the
mutations. CF being the rare disease, and due to the limited information
available, the extensive research is required. The research and development cost
for the cystic fibrosis is very high leading to the massive prices of the end
products. High cost of the drugs and treatments is one of the factors that
hinder the growth of the cystic fibrosis market.
Global Cystic Fibrosis
Market - Competitive Analysis:
The global market for cystic fibrosis is dominated by American
pharmaceutical company Vertex Pharmaceuticals Incorporated. With two FDA
approved CFTR modulator drugs Kalydeco & Orkambi, Vertex Pharmaceuticals
secured a top spot with the market share of 46% in the global cystic fibrosis
market. Kalydeco and Orkambi are the drugs that affect the disease at a genetic
level where as all the other drugs from different companies deal with the
disease symptoms and associated problems. Currently there is no competition for
the Kalydeco and Orkambi. Moreover the Vertex is on the verge of developing
their next and better drug “triple combo” which is expected to cover 90% of the
total identified CFTR mutations. This development is the strong reason for
Vertex pharmaceutical to be on top of the table in the near future as well.
Apart from the Vertex, there are some companies which are
manufacturing different drugs for the treatment for the cystic fibrosis. These
companies have drug products such as Roche- Pulmozyme, Abbvie- Creon, Gilead-
Cayston, Novartis- TOBI Podhaler, Allergan- Zenpep, Chiesi- Pertzye, and few
others. As these products help patients in managing the cystic fibrosis
symptoms and are consumed daily, these companies have fair amount of share in
the market. Additionally, there are other companies which such as Pharmaxis,
PTC therapeutics, Janssen Pharmaceuticals, Inc which are involved in the
development of the treatments for the symptoms of cystic fibrosis.
Global Cystic Fibrosis Market - Regional Analysis;
Cystic fibrosis can occur in both genders as well as in all ethnic
groups and races. However the incidences of cystic fibrosis varies across the
globe. Cystic fibrosis is more common among the Caucasians. Hence the disease
is more prevalent in North America, Europe, and Australia. However cystic
fibrosis can also affect Latinos, American Indians, African, and Middle Eastern
population.
North America is one of the majorly affected region by the deadly
disease cystic fibrosis. The United States is among the countries with highest
incidence rates of cystic fibrosis. According to cystic fibrosis foundation,
more than 30,000 patients are living with cystic fibrosis in the United States.
Nearly, 1000 new cystic fibrosis cases are diagnosed each year. According to
CFF’s national patient registry, the median age of the person with cystic
fibrosis is currently 33.4 years. The average life expectancy of the CF
patients has increased significantly as compared to the patients 30 years back.
European region is also largely affected by cystic fibrosis.
According to European Cystic Fibrosis Society (ECFS), considering the 26 major
countries in Europe, more than 35,500 people were suffering from cystic
fibrosis in 2014. Among the CF patients in Europe, 51.8% were adults with age
18 years or more and 48.2% were less than 18 years old. Countries like United
Kingdom, Ireland, Romania, and Bulgaria have the high birth prevalence of CF.
The prevalence of cystic fibrosis is seen to be very low in the
Asian region. There is limited information available about CF in Asia, it is
likely that the disease is highly underdiagnosed in this region including the
Indian subcontinent. It is due to medical community’s lack of knowledge about
CF and poor access to the medical and healthcare facilities for cystic fibrosis
patients.
The incidence of cystic fibrosis in Middle East varies according
to the ethnic background. However, the CF prevalence in Middle East is low as
compared to the North American and European region. There are no accurate CF
prevalence number for the Northern African countries, but it is expected to be
low due to the racial factor and no European genetic mixture.
Access Complete Report @ https://www.marketresearchfuture.com/reports/cystic-fibrosis-market-1825
About Market Research Future:
At Market Research Future (MRFR),
we enable our customers to unravel the complexity of various industries through
our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
MRFR team have supreme objective
to provide the optimum quality market research and intelligence services to our
clients. Our market research studies by Components, Application, Logistics and
market players for global, regional, and country level market segments, enable
our clients to see more, know more, and do more, which help to answer all their
most important questions.
In order to stay updated with
technology and work process of the industry, MRFR often plans & conducts
meet with the industry experts and industrial visits for its research analyst
members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
NOTE : Our team of researchers
are studying Covid19 and its impact on various industry verticals and wherever
required we will be considering covid19 footprints for a better analysis of
markets and industries. Cordially get in touch for more details.
